Drugs / BMS-986458
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06090539 | Dec 2023 → Oct 2027 expected | non-Hodgkin lymphoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986458 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06090539 ↗ |
| Target | BCL6 | “BMS-986458 induces rapid cereblon-dependent BCL6 degradation” PMID 41670385 ↗ Feb 2026 |